What is ABEC?
Since 1974, ABEC has established itself as a leader in delivering bespoke single-use, stainless steel, and hybrid solutions and services tailored for biopharmaceutical manufacturing. The company serves a broad spectrum of global pharmaceutical and biotech firms, with many of today's leading therapies relying on processes and equipment engineered, manufactured, installed, and serviced by ABEC. ABEC's distinct value proposition is built upon extensive experience, comprehensive in-house capabilities, a flexible and customized approach, and a proven track record of credibility. Whether clients are expanding capacity or optimizing existing operations, ABEC's turn-key solutions and support services are designed to reduce overall costs and accelerate time-to-market while maximizing productivity.
How much funding has ABEC raised?
ABEC has raised a total of $4M across 2 funding rounds:
Debt
$2M
Debt
$2M
Debt (2020): $2M with participation from PPP
Debt (2021): $2M led by PPP
What's next for ABEC?
The recent major strategic investment and enterprise-level funding indicate a period of significant operational expansion or technological advancement for ABEC. This capital infusion is likely to bolster the company's capacity to meet the growing demands of the biopharmaceutical sector, potentially enabling further innovation in its customized single-use, stainless steel, and hybrid manufacturing solutions. ABEC's strategic focus on reducing costs and time-to-market for its clients positions it for continued growth and influence within the industry, especially as global demand for advanced therapies escalates.
See full ABEC company page
